N🟁N

Debt conversion

  //business-finance.news-articles.net/content/2011/02/15/debt-conversion.html
  Published in Business and Finance on Tuesday, February 15th 2011 at 23:20 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

 16 February 2011 GB0001646941/GBP/PLUS-exn EDEN RESEARCH PLC ("Eden" or "Company") Debt conversion Eden Research plc, a leading UK agrochemical development company, is pleased to announce that GBP 2,000,000 of long term debt has been converted into 10,000,000 ordinary shares in the Company at a price of 20p. Following this debt conversion, Eden has 82,986,200 ordinary shares in issue, of which the Directors are interested in a total of 1,651,893 ordinary shares, representing 1.99 per cent of the Company's enlarged issued share capital, as follows: Director No of shares held % of enlarged share capital A Abrey 155,940 0.19 K Brooks 931,010 1.12 B Gill 385,848 0.46 C Newitt 179,095 0.22 The Directors of Eden are responsible for the contents of this announcement. Enquiries: Eden Research plc 01993 862761 Clive Newitt, Managing Director St Helens Capital Partners LLP 020 7368 6959 Mark Anwyl Notes: Eden's strategy is focused on the development and commercialisation of its terpene-based encapsulation technology for agricultural and non-agricultural uses through appropriate regional or global partnerships. Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries. Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides the unique, natural solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.